Polen Capital, an investment management company, released its “Polen Focus Growth Strategy” first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 was highly volatile for US equities, driven by AI disruption concerns and the US-Israel conflict in Iran and the Middle East. In this backdrop, the Polen Focus Growth Strategy declined 17.16% in the quarter, compared to a -9.78% return for the Russell 1000 Growth and -4.33% return for the S&P 500. The Strategy focuses on mission-critical businesses with recurring revenue and competitive advantages and capitalizes on the volatility to increase investments in software and semiconductor companies. The Strategy remains confident in the long-term potential of the Portfolio, emphasizing businesses with strong economic moats, robust balance sheets, and multi-year earnings growth. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Polen Focus Growth Strategy highlighted stocks such as Boston Scientific Corporation (NYSE:BSX). Boston Scientific Corporation (NYSE:BSX) is a medical technology company that manufactures and markets medical devices for use in various interventional medical specialties. On April 28, 2026, Boston Scientific Corporation (NYSE:BSX) closed at $58.45 per share. One-month return of Boston Scientific Corporation (NYSE:BSX) was -5.73%, and its shares lost 43.18% over the past 52 weeks. Boston Scientific Corporation (NYSE:BSX) has a market capitalization of $86.87 billion.
Polen Focus Growth Strategy stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q1 2026 investor letter:
“We also sold Boston Scientific Corporation (NYSE:BSX) over concerns around increasing competition in its electrophysiology business, which is key to the company’s long-term growth profile. While we think their growth profile remains solid even with the competition and a reasonable valuation, we are seeing more compelling opportunities elsewhere and so are redeploying that capital to those ideas.”
Boston Scientific Corporation (NYSE:BSX) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 110 hedge fund portfolios held Boston Scientific Corporation (NYSE:BSX) at the end of the fourth quarter, up from 102 in the previous quarter. In the first quarter of 2026, Boston Scientific Corporation (NYSE:BSX) delivered consolidated revenue of $5.203 billion representing a 11.6% year-over-year growth compared to Q1 2025. While we acknowledge the risk and potential of Boston Scientific Corporation (NYSE:BSX) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Boston Scientific Corporation (NYSE:BSX) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Boston Scientific Corporation (NYSE:BSX) and shared the list of stocks Jim Cramer discussed. In addition, please check out our hedge fund investor letters Q1 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
